


- (b) obtaining a sample containing TCR-T cells from the mammal;
- (c) restimulating said T-cells in said sample with said antigen;
- (d) monitoring the levels of IL-5 or IFN- γ or both IL-5 and IFN- γ in said sample.

12. The method of claim 1 wherein step (b) comprises administering nucleic acid encoding said antigen to the mammal by particle mediated gene delivery.

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/GB00/03730 into the U.S. National Phase of prosecution. Claims 2-12 have been amended to eliminate multiple dependencies and to comply with proper U.S. claim format. Furthermore, attached hereto is a marked-up version of the changes made to the application by the current preliminary amendment. The attached page is captioned, "**Version with markings to show changes made.**"

Respectfully submitted,



William R. Majarian
Attorney for Applicants
Registration No. 41,173

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5968
Facsimile (610) 270-5090

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

CROSS REFERENCES TO RELATED APPLICATIONS

This newly added paragraph to the specification is solely to incorporate continuing application data. No changes have been made. Therefore, a marked up version is not required.

The newly added page to the specification is solely to incorporate the Abstract page. No changes have been made, therefore, a marked up version is not required.

In the claims:

2. ~~A~~The method according to claim 1 further comprising isolating a sample containing TCR-T cells from said mammal after step (b), and restimulating said sample with the antigen prior to step (c).

3. ~~A~~The method according to claim 1 ~~or claim 2~~ wherein step (c) comprises monitoring the TCR-T-cell population.

4. ~~A~~The method according to claim 1 ~~or claim 2~~ wherein step (c) comprises monitoring cytokine production by said TCR-T-cells.

5. ~~A~~The method according to claim 4 wherein the cytokine is at least one member selected from the group consisting of interferon(and/or IL-5.

6. ~~A~~The method according to claim 5 wherein the levels of both IFN- γ and IL-5 are measured.

7. ~~A~~The method according to claim 1 ~~or claim 2~~ where step(c) comprises monitoring cell-surface markers on TCR T-cells.

8. ~~A~~The method according to ~~any preceding claim for assessing a T-cell helper response~~ 1 wherein step (c) comprises assessing an immune response associated with said TCR-T-cells that is indicative of a T-cell helper response.

9. ~~A~~The method according to ~~any one of claims 1 to 7~~ for assessing a cytotoxic T-cell responses, wherein step (c) comprises assessing an immune response associated with said TCR-T-cells that is indicative of a cytotoxic T-cell response.

10. ~~A~~The method according to ~~any one of claims 1-7~~ for assessing a memory T-cell response wherein step (c) comprises assessing an immune response associated with said TCR-T-cells that is indicative of a memory T-cell response.

11. A method of monitoring a T-cell helper response comprising
(a) administering nucleic acid encoding an antigen to a mammal having had transferred thereto T-cells expressing a T-cell receptor for said antigen (TCR-T-cells);
(b) obtaining a sample containing TCR-T cells from the mammal;
(c) restimulating said T-cells in said sample with said antigen;
(d) monitoring the levels of IL-5 ~~and/or IFN- γ~~ or both IL-5 and IFN- γ in said sample.

12. ~~A~~The method according to ~~any one of the preceding claims 1~~ wherein step (b) comprises administering nucleic acid encoding said antigen to the mammal by particle mediated gene delivery.